On April 20, 2022 Cytokinetics, Incorporated (Nasdaq: CYTK) reported that it is scheduled to report first quarter results on May 4, 2022 at 4:00 PM Eastern Time (Press release, Cytokinetics, APR 20, 2022, View Source [SID1234612856]). Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call will be simultaneously webcast and can be accessed from the homepage and in the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by dialing either (866) 999-CYTK (2985) (United States and Canada) or (706) 679-3078 (international) and typing in the passcode 5771758.

An archived replay of the webcast will be available via Cytokinetics’ website until May 18, 2022. The replay will also be available via telephone by dialing (855) 859-2056 (United States and Canada) or (404) 537-3406 (international) and typing in the passcode 5771758 from May 4, 2022 at 8:00 PM Eastern Time until May 18, 2022.

On April 20, 2022 EpiAxis Therapeutics reported that it was thrilled to attend and present at the ACCESS CHINA Biotech Forum Spring Showcase 2022 earlier this month (Press release, EpiAxis Therapeutics, APR 20, 2022, View Source;utm_medium=rss&utm_campaign=epiaxis-therapeutics-presents-access-china [SID1234612827]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ACCESS CHINA Biotech Forum is one of the largest corporate access events in China. It provides opportunities for business development, licensing deals and commercial collaborations to global biopharmas. It has been held every quarter since 2020 and has been bringing together international and Chinese biotech BDs and CEOs over the past two years.

The 2022 ACCESS CHINA forum was held online from 18-19 April 2022, attracting more than 1000 participants from China pharma and biotech companies.

EpiAxis CEO Dr Jeremy Chrisp presented during the US and Australia biotech Company Roadshows sessions. His video presentation focused on overcoming resistance to standard of care cancer treatments with novel epigenetic cancer therapies.

Dr Chrisp explained that the primary focus at EpiAxis Therapeutics is the initial treatment and subsequent prevention of recurrence of cancer using proprietary LSD1 inhibitors.

"We are seeking capital to allow us to complete our program to advance one of our therapeutics into the clinic," Dr Chrisp said. "We believe LSD1 is the pivotal enzyme controlling cancer regression. Our thesis is directed towards inhibiting nuclear LSD1 and we believe it allows us to reprogram cancer cells and immune cells to offer a new way to treat aggressive cancer."

On April 20, 2022 Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, reported that it closed its previously announced senior secured credit facilities (Press release, Perrigo Company, APR 20, 2022, View Source [SID1234612658]). The new facilities consist of (i) a $1.0 billion five-year revolving credit facility (the "New Revolving Facility"), (ii) a $500 million five-year term loan A facility (the "New Term Loan A Facility"), and (iii) a $1.1 billion seven-year term loan B facility (the "New Term Loan B Facility" and, together with the New Term Loan A Facility, the "New Term Loan Facilities," and the New Term Loan Facilities together with the New Revolving Facility, the "New Senior Secured Credit Facilities") . Due to the favorable reception from the market to the syndication of the New Senior Secured Credit Facilities, the size of the New Term Loan Facilities was increased to a total of $1.6 billion from the previously announced $1.1 billion, and the Company has decided not to proceed with its previously announced offering of senior notes. The New Senior Secured Credit Facilities are being incurred by the Company’s wholly-owned subsidiary, Perrigo Investments, LLC, and will be guaranteed by the Company and certain other wholly-owned subsidiaries of the Company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will use the proceeds of the New Term Loan Facilities, together with cash on hand, to finance the previously announced acquisition of Héra SAS ("Héra") and to repay existing indebtedness of the Company and its subsidiaries under its outstanding term loan facility, its 4.00% Senior Notes due 2023 and its 5.1045% Guaranteed Senior Notes due 2023. Notice of redemption of the 4.00% Senior Notes due 2023 and the 5.1045% Guaranteed Senior Notes due 2023 has been given, and the notes will be redeemed on May 20, 2022. The Company will use any amounts borrowed from time to time under the New Revolving Facility, which will replace its existing revolving facility, for general corporate purposes.

JPMorgan Chase Bank, N.A., Morgan Stanley Senior Funding, Inc., Wells Fargo Securities, LLC, BofA Securities, Inc. and HSBC Securities (USA) Inc. are the joint lead arrangers for the New Senior Secured Credit Facilities.

On April 20, 2022 BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) reported that the company’s partner AbbVie has decided to terminate its collaboration with BioArctic regarding the portfolio of alpha-synuclein antibodies, including ABBV-0805 (Press release, AbbVie, APR 20, 2022, View Source [SID1234612604]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BioArctic and AbbVie have collaborated since 2016 regarding the research and development of BioArctic’s portfolio of alpha-synuclein antibodies for Parkinson’s disease and other potential indications. In 2019, a Phase 1 study of the lead asset, ABBV-0805, was initiated, and results from the study, presented at the International Congress of Parkinson’s Disease and Movement Disorders (MDS) in September 2021, supports a continuation into Phase 2 with once-monthly dosing.

"We are disappointed that AbbVie has taken this decision. All available data indicates that ABBV-0805 has uniquely high selectivity for the pathological forms of aggregated alpha-synuclein, as well as Phase 1 data supporting progression to Phase 2. We believe that ABBV-0805 has the potential to become a disease-modifying treatment for people with Parkinson’s disease and will now investigate options to continue the development of this asset," says Gunilla Osswald, BioArctic’s CEO.

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.

This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, on April 20, 2022, at 07:50 a.m. CET.  

About ABBV-0805

ABBV-0805 is a monoclonal antibody drug candidate that is designed to selectively bind and eliminate aggregated forms of alpha-synuclein such as oligomers and protofibrils, which participates in neurodegenerative maladies including Parkinson’s disease. The goal is to develop a disease modifying treatment that stops or slows down the progression of Parkinson’s disease.

About the collaboration between BioArctic and AbbVie

BioArctic has been collaborating with AbbVie since 2016, when the two companies entered into a research agreement. AbbVie then obtained the right to acquire a license to develop and commercialize BioArctic’s portfolio of alpha-synuclein antibodies for Parkinson’s disease and other potential indications. In late 2018, AbbVie exercised this option. In 2019, a Phase 1 study of ABBV-0805 was initiated. Results from the study, presented in September 2021, support a continuation into Phase 2. AbbVie has been managing and funding the clinical development of ABBV-0805. The scope of the drug candidate ABBV-0805 may be broadened to include, for example, Lewy body dementia and multiple system atrophy.

On April 20, 2022 Samsung Biologics (KRX: 207940.KS) reported that it has completed the purchase of Biogen’s stake in the Samsung Bioepis joint venture for USD $2.3 billion (Press release, Samsung BioLogics, APR 20, 2022, View Source [SID1234612603]). With the completion of the first payment of USD $1.0 billion pursuant to the terms of the acquisition agreement, Samsung Biologics has now fully acquired Samsung Bioepis as a wholly owned subsidiary. The remaining USD $1.3 billion will be made in installments over two years.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Today’s announcement marks a significant milestone for Samsung Biologics in our continued venture into the biosimilar business and accelerating biosimilar growth," said John Rim, CEO and President of Samsung Biologics. "By leveraging our extensive experience as a leading CDMO, we will further contribute to saving lives of the patients and address a wide array of diseases."

The purchase was funded by a portion of paid-in capital increase of KRW 3 trillion (approximately USD $2.5 billion) raised by issuing new shares, the proceeds of which will be used to fund the company’s strategic growth plans. The acquisition gives Samsung Bioepis improved autonomy and agility in business operations, accelerating sales growth, operating margin improvements, as well as biosimilar development capabilities and future performance in novel drug development.

Samsung Biologics will continue to deliver on its commitment to clients and shareholders by providing quality-driven CDMO biomanufacturing services. The company is currently building Plant 4, which will partially become operational in October 2022. In addition, Samsung Biologics is in the process of securing additional land of 350,000m2 for Bio Campus II, which will be 30% larger than the size of the current site for future growth.